Custom Search
|
|
Lesions Simulating Malignant Pleural Mesothelioma
Another study is called, “Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural Mesothelioma” by G. Falconieri, R. Bussani1, M. Mirra, M. Zanella – Histopathology Volume 30, Issue 5, pages 419–424, May 1997. Here is an excerpt: “We report two cases of autopsy confirmed angiosarcoma in adult males, presenting as diffuse pleuropulmonary tumours and simulating malignant mesothelioma. Both the lesions grew along the serosal surfaces and were characterized by variably thick rinds of tissue encasing the lung. The pulmonary parenchyma showed diffuse, dark red, subpleural consolidations and multiple cavitations. Histologically, the lesions were composed by atypical spindle and polygonal, epithelioid cells showing rudimentary vascular differentiation and exhibiting strong positivity for factor VIII, CD31, CD34 and vimentin. We conclude that angiosarcoma may present with preponderant or exclusive involvement of pleura and peripheral lung and that it should be added to the list of tumours capable of simulating malignant mesothelioma.” Another study is called, “D2-40: A Reliable Marker in the Diagnosis of Pleural Mesothelioma” by Annette M. Müllera, Folker E. Frankeb, Klaus-Michael Müllera - Institute of Pathology, BG Clinics ‘Bergmannsheil’, Ruhr University Bochum, Bochum, and Justus Liebig University, Giessen, Germany - Pathobiology 2006;73:50-54. Here is an excerpt: “Abstract - Objective: Malignant mesotheliomas of the pleura, peritoneum and pericardium can easily be confused with either metastatic adenocarcinomas or reactive pleural lesions. D2-40, a monoclonal antibody used as a marker for seminomatous germ cell tumours and lymphatic endothelial cells, was recently described in mesothelial cells and type I but not type II pneumocytes. Method: The immunoreactivities of D2-40 in 76 lung carcinomas of different histological types (adenocarcinomas, squamous cell, small cell, and bronchioloalveolar carcinomas) were compared with those of 36 pleural epithelioid and sarcomatoid mesotheliomas and 5 specimens of chronic pleuritis. Results: While all 18 analysed epithelioid mesotheliomas displayed a strong membranous immunostaining, 18 sarcomatoid mesotheliomas showed no, or a merely faint, cytoplasmic signal, comparable with fibroblasts in chronic pleuritis. Out of all analysed lung carcinomas, 49 showed no immunoreactivity for D2-40 (64%), while the other 27 (36%) showed a focal weak to moderate and only cytoplasmic signal. Conclusions: We regard D2-40 as a valid marker in the differential diagnosis of epithelioid mesotheliomas versus pulmonary adenocarcinomas. However, this marker may not properly label sarcomatoid mesotheliomas or distinguish them from reactive pleural lesions.” We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety. Article Directory: http://www.articledashboard.com Monty Wrobleski is the author of this article. For more information please click on the following links Mesothelioma Lawyer Mesothelioma Lawyer Mesothelioma Lawyer |
|
© 2005-2011 Article Dashboard